

28th August 2025

To

The BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001	National Stock Exchange of India Limited “Exchange Plaza, Bandra Kurla Complex, Bandra (E) Mumbai - 400051
Scrip Code: 517556	Symbol: PVP Debt-18PVL29A, 18PVL29

Dear Sir/Madam,

Subject: Intimation under Regulation 30 & 51 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (“Listing Regulations”) – Outcome of the Board Meeting

Pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e., August 28, 2025, has considered and approved the proposal for the acquisition of a majority stake in **7Med India Pvt. Ltd.** (“7Med” / “Company”), a healthcare enterprise headquartered in the Delhi NCR region.

7Med was established by a team of highly respected specialists in Nephrology, Urology, and Dialysis, and is dedicated to bridging the existing gaps in care for patients suffering from kidney failure. The company delivers holistic, world-class renal care across geographies. Its operations encompass a profitable network of 22 state-of-the-art centres, including shop-in-shop dialysis facilities within leading hospitals and standalone dialysis units across six states. In addition, 7Med operates four super-specialty hospitals with a focused expertise in Nephrology and Urology.

To give effect to the proposed acquisition, the Board has also approved the execution of definitive agreements, including the Share Purchase Agreement and other ancillary documents, setting out the terms and conditions of the transaction, to be entered into between the Company, 7Med, and other relevant parties.

WHERE YOU WANT TO BE[®]



Further details of the transaction, as required under the SEBI Listing Regulations, are enclosed herewith as **Annexure-I**.

The Board meeting commenced at 11:30 A.M. IST and concluded at 11. 50 A.M. IST.

This is for your information and records.

Kindly take the above information on records.

For PVP Ventures Limited

**Prasad V Potluri
Chairman & Managing Director**

Attached: As in above

Annexure-I

Details required to be provided while disclosing event under Regulation 30 Para A of Schedule III of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/0155 dated 11 November 2024:

S.NO	PARTICULARS	DETAILS
1	Name of the target entity, details in brief such as size, turnover etc.;	7Med India Pvt. Ltd.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	The investment does not fall within the ambit of Related Party Transactions and the promoters/ promoter group/ group companies of the Company do not have any existing interest either directly/indirectly in the entity being acquired.
3	Industry to which the entity being acquired belongs;	Healthcare
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Expansion into the healthcare sector.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Nil
6	Indicative time period for completion of the acquisition;	The company has entered into a binding agreements to initially acquire 41.2% stake in 7 Med India Pvt. Ltd. with a clear contracted path to majority shareholding within 12 months from today.
7	Consideration -whether cash consideration or share swap or any other form and details of the same;	Cash consideration.

8	Cost of acquisition and/or the price at which the shares are acquired	The transaction shall be a combination of both primary and secondary stake purchase amounting to an outlay of circa INR 127 crores for this majority shareholding.
9	Percentage of shareholding / control acquired and / or number of shares acquired	The company has entered into a binding agreements to initially acquire 41.2% stake in 7 Med India Pvt. Ltd. with a clear contracted path to majority shareholding within 12 months from today.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	7Med India Pvt Ltd is among the top five organized players in India's renal care sector, offering a comprehensive range of dialysis services across its pan-India network. The target company has reported an EBITDA of approximately INR 10 crore for the current financial year.

For PVP Ventures Limited

**Prasad V Potluri
Chairman & Managing Director**

PVP Ventures Limited acquires significant stake in one of India's Top Dialysis and Nephrology services provider - 7 Med India Pvt Ltd. and Epitome Group of Hospitals

PVP Ventures Ltd., (“PVP”) executed binding agreements to initially acquire 41.23% stake in 7 Med India Pvt. Ltd. and Epitome Group of Hospitals (“7Med” / “Company”) with a clear contracted path to majority shareholding within 12 months from date of this announcement and a defined roadmap to increase its stake to 76% over time. With this acquisition, PVP has made a significant stride in its earlier announced plans to build a new age global Healthcare Services platform focussing on Illness, Wellness and Care.

The transaction shall be a combination of both primary and secondary stake purchase amounting to an outlay of circa INR 127 crores for this majority shareholding. The subsequent investments are subject to achievement of financial benchmarks contractually laid out over the next few years.

Headquartered in the Delhi NCR region, 7Med & Epitome Hospitals were founded and are run by a group of reputed and thought leaders in Nephrology, Urology, and Dialysis specialisations. The company today employs over 450 professionals and is spearheaded by a team of highly skilled and experienced founders who have served in leadership positions with organisations such as Fresenius Medical Care, B. Braun Medical, Medanta Group, and Fortis Group, among others. The Company is committed to bridging the care gap by providing holistic, world-class care to kidney failure patients across geographies.

The Company operates a profitable network of 22 cutting-edge establishments, including shop-in-shop dialysis centres within leading hospitals and standalone dialysis centres across 6 states, as well as 4 super-speciality hospitals with a clear focus on Nephrology and Urology.

With an EBITDA of approximately INR 10 crores in the current financial year, the Company is poised to deliver an EBITDA of INR 50 crores in the next 4 years with the current investment. It is already among the top five organised players in India's renal care space, offering the entire spectrum of dialysis services across its national footprint. With the capital infusion from PVP Ventures Ltd., the Company plans to expand its network to multiple states and significantly enhance healthcare infrastructure in Tier 2 and Tier 3 cities and towns in these identified states.

Mr. Gaurav Davda, Head of M&A and Strategy - PVP Ventures Ltd. said, “This transaction represents a significant step in our journey in creating a powerful house of brands in Healthcare Services focused on Tier 2 and Tier 3 markets in key identified specialisations. We



welcome 7Med and its team into the PVP fold and look forward to enabling them to become a scaled national player in the near future”

Dr. Vijay Kher, Shareholder -7 Med India Pvt. Ltd. & Chairman – Epitome Hospitals, said ,“This collaboration marks a significant milestone in the Healthcare sector, combining clinical excellence and innovative healthcare solutions to create a stronger, more future-ready organisation for delivering affordable, high-quality kidney care. We now aim to reach new geographies, expand patient-centric healthcare services, and enhance operational efficiencies through integrated resources.”

About PVP Ventures Limited (“PVP”)

With a stated goal of building technology lead house of brands in the universe of Healthcare services, PVP is fast tracking its presence and growth through acquisitions. The Company has entered into development agreements with industry leaders such as Brigade Enterprises Ltd. and Casagrand Premier Builder Ltd. for monetising its legacy realty asset. With expected cash flows from these developments in excess of INR 2000 crores over the next 6 years, PVP is deploying the resources in the global healthcare services sector to evolve as an industry leader and create sustainable value for its stakeholders.

About 7Med India Pvt. Ltd. & Epitome Hospitals (“Company”)

7Med India Pvt. Ltd. and Epitome Hospitals stand as torchbearers of excellence in Dialysis, Nephrology, and Urology, founded by an eminent team of visionaries - **Dr. Vijay Kher, Dr. Sudhanshu Tyagi, Mr. Ashish Tyagi, Dr. Ajay Kher ,Mr. Vikas Verma, Mr. Mayank Sharma and Dr. Rakesh Thakur-** each bringing decades of clinical mastery, entrepreneurial acumen, and leadership experience from some of the world’s most respected healthcare institutions. From establishing state-of-the-art dialysis centres within leading hospitals to operating a robust network of owned centres and super-specialised hospitals, the Group has touched the lives of thousands of patients nationwide. Having conducted more than a million dialysis procedures to date, the organisation is on a trajectory to multiply this impact many times over in the coming years.

This communication contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties. Accordingly, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein. Even when subsequent changes in conditions or other circumstances make it preferable to update or revise forecasts, plans, or other forward-looking statements, the Company disclaims any obligation to update or revise this communication..

